drugset / Trial / NCT01014416

Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male

NCT01014416

Phase 1 Completed 46 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

To investigate the safety, tolerance, pharmacokinetics and pharmacodynamics of tolvaptan 15, 30 and 60 mg after single oral administration in healthy Korean male subjects.

Timeline

Start
2010-01
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolvaptan Small molecule 15 mg Oral
Subject Tolvaptan Small molecule 30 mg Oral
Subject Tolvaptan Small molecule 60 mg Oral

Indications

No indication recorded.